COMMUNIQUÉS West-GlobeNewswire

Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

29/08/2018 - 13:00

OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company’s [...]

Kamada Provides Updated Full-Year 2018 Revenue Guidance

29/08/2018 - 13:00

As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year REHOVOT, Israel, Aug. 29, 2018 ( [...]

Chimerix to Participate in September Investor Conferences

29/08/2018 - 13:00

DURHAM, N.C., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that company management will participate in [...]

Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference

29/08/2018 - 13:00

FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated [...]

CLINUVEL delivers second positive financial result

29/08/2018 - 12:52

European revenues re-invested in novel R&D MELBOURNE, Australia, Aug. 29, 2018 (GLOBE NEWSWIRE) -- EXECUTIVE SUMMARY – FINANCIAL YEAR 01 JULY TO 30 JUNE 2017/18 2016/17 Change Total Revenues $25.750m $16.984m 52% [...]

Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018

29/08/2018 - 11:00

Three presentations focus on Poseida’s clinical and preclinical CAR-T programs SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene [...]

Enzymatica AB: Appeal of court ruling on Enzymatica's cold spray in Germany

29/08/2018 - 08:30

Press release August 29, 2018 Appeal of court ruling on Enzymatica's cold spray in Germany Enzymatica's distributor in Germany has appealed to the regional court of Frankfurt on their decision to put restrictions on the [...]

Herantis Pharma Plc's half year financial report January 1 - June 30, 2018 (unaudited)

29/08/2018 - 08:01

Herantis Pharma Plc Company release August 29, 2018 at 9:00am Drug development progresses in randomized trials Herantis Pharma Plc's half year financial report January 1 - June 30, 2018 (unaudited) Highlights in January [...]

Shire plc: Rule 2.9 Announcement

29/08/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 29 August 2018 [...]

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 21st tranche of investment today

29/08/2018 - 07:18

Amsterdam, The Netherlands - 29 August 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 21 st Tranche of EUR 300,000 is issued as a private placement of 30 convertible notes (the " [...]

European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma

29/08/2018 - 07:16

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are likely to recur to stage [...]

Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma

29/08/2018 - 07:01

Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising commitment to patient safety [...]

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis

29/08/2018 - 07:01

August 29, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Canada House Wellness Group Reports Fiscal Year 2018 Results

29/08/2018 - 03:08

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“ Canada House ” or the “ Company ”) is [...]

Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma

29/08/2018 - 01:16

– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study – – The trial will use product produced from Gradalis’ recently- [...]

Free Health Visits, Available Through Teladoc Health, to Residents Impacted by Hurricane Lane

28/08/2018 - 23:22

Residents and Those Displaced Can Call 855-549-2234 to Access Treatment for Non-Emergency Illnesses PURCHASE, NY, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, is [...]

SeaSpine to Participate in the 13th Annual Wells Fargo Securities Healthcare Conference (corrected time)

28/08/2018 - 23:15

CARLSBAD, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]

UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018

28/08/2018 - 23:04

WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the [...]

Assertio Therapeutics and Purdue Pharma Settle Patent Infringement Lawsuit

28/08/2018 - 22:36

Purdue to pay Assertio $62 million in two installments LAKE FOREST, Ill., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the Company has entered into a settlement [...]